PepGen Inc
PEPG1.285USD
-0.035-2.65%
交易中 （美東）報價延遲15分鐘
42.05M總市值
虧損本益比TTM
關於 PepGen Inc 公司
PepGen Inc. 是一家臨牀階段的生物技術公司。該公司致力於推進下一代寡核苷酸療法，旨在改變嚴重神經肌肉和神經系統疾病的治療方法。其專有的增強遞送寡核苷酸 (EDO) 平臺利用細胞穿透肽來改善結合寡核苷酸療法的吸收和活性。其 EDO 肽經過精心設計，可優化組織滲透、細胞吸收和核遞送。利用這些 EDO 肽，該公司正在生成一系列寡核苷酸治療候選藥物，旨在針對嚴重疾病的根本原因。該公司的管線包括兩個臨牀階段項目：用於適合外顯子 51 跳躍的杜氏肌營養不良症 (DMD) 患者的 PGN-EDO51 和用於 1 型肌強直性營養不良症 (DM1) 患者的 PGN-EDODM1。它還有另外三個臨牀前階段項目：PGN-EDO53、PGN-EDO45 和 PGN-EDO44。
公司簡介
公司代碼PEPG
公司名稱PepGen Inc
上市日期May 06, 2022
CEODr. James G. Mcarthur, Ph.D.
員工數量81
證券類型Ordinary Share
年結日May 06
公司地址245 Main St, 2nd Floor
城市CAMBRIDGE
上市交易所NASDAQ Global Select Consolidated
國家United States of America
郵編02142
電話17034568000
網址https://pepgen.com
公司代碼PEPG
上市日期May 06, 2022
CEODr. James G. Mcarthur, Ph.D.
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Dr. James G. Mcarthur, Ph.D.
Dr. James G. Mcarthur, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
53.19K
+3040.14%
Ms. Laurie Bartlett Keating, J.D.
Ms. Laurie Bartlett Keating, J.D.
Independent Chairman of the Board
Independent Chairman of the Board
4.17K
--
Ms. Mary Beth Delena, J.D.
Ms. Mary Beth Delena, J.D.
General Counsel, Company Secretary
General Counsel, Company Secretary
1.43K
-8.67%
Mr. Habib Joseph Dable
Mr. Habib Joseph Dable
Independent Director
Independent Director
--
--
Ms. Heidi Henson, CPA
Ms. Heidi Henson, CPA
Independent Director
Independent Director
--
--
Dr. Paul D. Streck, M.D.
Dr. Paul D. Streck, M.D.
Executive Vice President, Head of Research & Development
Executive Vice President, Head of Research & Development
--
--
Mr. Noel P. Donnelly
Mr. Noel P. Donnelly
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Joshua B. (Josh) Resnick, M.D.
Dr. Joshua B. (Josh) Resnick, M.D.
Independent Director
Independent Director
--
--
Dr. Howard Mayer, M.D.
Dr. Howard Mayer, M.D.
Independent Director
Independent Director
--
--
Dr. Kasra Kasraian, Ph.D.
Dr. Kasra Kasraian, Ph.D.
Chief Technology Officer
Chief Technology Officer
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. James G. Mcarthur, Ph.D.
Dr. James G. Mcarthur, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
53.19K
+3040.14%
Ms. Laurie Bartlett Keating, J.D.
Ms. Laurie Bartlett Keating, J.D.
Independent Chairman of the Board
Independent Chairman of the Board
4.17K
--
Ms. Mary Beth Delena, J.D.
Ms. Mary Beth Delena, J.D.
General Counsel, Company Secretary
General Counsel, Company Secretary
1.43K
-8.67%
Mr. Habib Joseph Dable
Mr. Habib Joseph Dable
Independent Director
Independent Director
--
--
Ms. Heidi Henson, CPA
Ms. Heidi Henson, CPA
Independent Director
Independent Director
--
--
Dr. Paul D. Streck, M.D.
Dr. Paul D. Streck, M.D.
Executive Vice President, Head of Research & Development
Executive Vice President, Head of Research & Development
--
--
收入明細
暫無數據
暫無數據
業務
地區
暫無數據
股東統計
更新時間: 5月23日 週五
更新時間: 5月23日 週五
持股股東
股東類型
持股股東
持股股東
佔比
RA Capital Management, LP
32.67%
Oxford Science Enterprises PLC
14.53%
Point72 Asset Management, L.P.
8.18%
Suvretta Capital Management, LLC
5.08%
Viking Global Investors LP
4.53%
Other
35.01%
持股股東
持股股東
佔比
RA Capital Management, LP
32.67%
Oxford Science Enterprises PLC
14.53%
Point72 Asset Management, L.P.
8.18%
Suvretta Capital Management, LLC
5.08%
Viking Global Investors LP
4.53%
Other
35.01%
股東類型
持股股東
佔比
Venture Capital
47.26%
Hedge Fund
27.63%
Investment Advisor/Hedge Fund
8.80%
Investment Advisor
8.03%
Sovereign Wealth Fund
3.80%
Research Firm
0.46%
Individual Investor
0.27%
Pension Fund
0.06%
Bank and Trust
0.05%
Other
3.65%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
165
31.53M
96.35%
-5.19M
2025Q1
168
31.44M
96.09%
-5.26M
2024Q4
160
31.09M
95.12%
-3.10M
2024Q3
156
31.41M
96.35%
-1.62M
2024Q2
150
31.22M
97.59%
-974.84K
2024Q1
140
30.76M
96.24%
+4.98M
2023Q4
127
22.26M
93.52%
+3.25M
2023Q3
124
22.70M
95.37%
+3.35M
2023Q2
119
23.17M
97.35%
+3.81M
2023Q1
108
18.62M
78.36%
-609.71K
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
RA Capital Management, LP
10.69M
32.67%
--
--
Mar 31, 2025
Oxford Science Enterprises PLC
4.76M
14.53%
--
--
Mar 31, 2025
Point72 Asset Management, L.P.
2.68M
8.18%
+804.74K
+43.01%
Mar 31, 2025
Suvretta Capital Management, LLC
1.66M
5.08%
--
--
Mar 31, 2025
Viking Global Investors LP
1.48M
4.53%
--
--
Mar 31, 2025
Adage Capital Management, L.P.
1.35M
4.13%
+550.00K
+68.75%
Mar 31, 2025
Qatar Investment Authority
1.24M
3.8%
--
--
Sep 30, 2024
BlackRock Institutional Trust Company, N.A.
1.19M
3.64%
+2.10K
+0.18%
Mar 31, 2025
Millennium Management LLC
1.03M
3.16%
+876.38K
+559.50%
Mar 31, 2025
The Vanguard Group, Inc.
899.73K
2.75%
-12.94K
-1.42%
Mar 31, 2025
查看更多
持股ETF
更新時間: 8月2日 週六
更新時間: 8月2日 週六
機構名稱
佔比
ProShares Ultra Nasdaq Biotechnology
0%
Proshares Ultra Russell 2000
0%
Invesco Dorsey Wright SmallCap Momentum ETF
0%
iShares Russell 2000 Value ETF
0%
Global X Russell 2000 ETF
0%
DFA Dimensional US Core Equity Market ETF
0%
iShares Russell 2000 Growth ETF
0%
Avantis US Small Cap Equity ETF
0%
ProShares UltraPro Russell2000
0%
iShares Micro-Cap ETF
0%
查看更多
ProShares Ultra Nasdaq Biotechnology
佔比0%
Proshares Ultra Russell 2000
佔比0%
Invesco Dorsey Wright SmallCap Momentum ETF
佔比0%
iShares Russell 2000 Value ETF
佔比0%
Global X Russell 2000 ETF
佔比0%
DFA Dimensional US Core Equity Market ETF
佔比0%
iShares Russell 2000 Growth ETF
佔比0%
Avantis US Small Cap Equity ETF
佔比0%
ProShares UltraPro Russell2000
佔比0%
iShares Micro-Cap ETF
佔比0%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
